Artificial Intelligence in COPD is transforming disease management, from underdiagnosis to treatment guidance. Discover how machine learning clusters patients, predicts outcomes, and optimizes healthcare resources.
Discover the normal ranges of fractional exhaled nitric oxide (FeNO) across different age groups in a respiratory healthy population. Based on 2,251 participants, this study identifies factors like age, body height, and eosinophil counts that influence FeNO levels.
Explore the causes of reduced FEV1 in early adulthood, with data from Lifelines and BAMSE cohorts. Findings highlight PRISm and airflow limitation origins, early identification in childhood, and differentiated clinical implications.
Discover the first study designed to analyze the impact of EVLP on the lung microbiome and the local inflammatory response. Understanding the composition, diversity, and functional interactions of the pulmonary microbiome in lung transplants holds promise for personalized respiratory medicine.
Accede a la inscripción en Streaming de Chiesi PatienTalks 2024, que tendrá lugar el próximo 26 de Noviembre de 2024, de 16 a 19h
This study explores how changes in the respiratory microbiome relate to systemic inflammation in COPD patients. It highlights correlations between bacterial abundance, eosinophilic markers, and airflow limitation severity.
¿Por qué la investigar en un hospital? Porque la investigación médica en hospitales es la ÚNICA forma en la que la medicina puede avanzar.
Explore how the COVID-19 Sentinel Schools Network of Catalonia monitored CO2 and NO2 levels in classrooms, revealing key findings on ventilation and air quality in schools across Catalonia during the pandemic.
A study that identifies four lung function trajectories in children, highlighting that physical activity and BMI at 4 years predict catch-up lung function growth, particularly zFEV1, but not zFVC.
Explore the complex pathophysiology of bronchiectasis, including airway infection, chronic inflammation, and mucociliary dysfunction. Learn how genomic approaches, proteomics, and epigenomics offer new insights into disease endotypes and patient stratification for improved therapies. Discover the role of trained innate immunity in complementing current models.
